Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Significant Decrease in Short Interest

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 77,700 shares, a decline of 38.7% from the January 31st total of 126,800 shares. Based on an average daily trading volume, of 55,600 shares, the days-to-cover ratio is currently 1.4 days. Currently, 0.6% of the shares of the stock are short sold.

Akari Therapeutics Price Performance

Shares of AKTX opened at $0.87 on Friday. Akari Therapeutics has a 1-year low of $0.86 and a 1-year high of $4.40. The firm has a 50 day simple moving average of $1.15 and a 200-day simple moving average of $2.02.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Akari Therapeutics in a report on Saturday, February 22nd. They set a “sell” rating for the company.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.